专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JPS5978122A Preparation of colony stimulating factor 失效
标题翻译：菌落刺激因子的制备
公开(公告)号：JPS5978122A
公开(公告)日：1984-05-04
申请号：JP18879382
申请日：1982-10-27
申请人： Ajinomoto Co Inc
发明人： IZAWA MASAAKI , AKIYAMA YUKIO , KASHIMA SHINICHI , YOSHIMOTO RIYOUTA , HAMURO JIYUNJI
IPC分类号： C12P21/00 , A61K35/12 , A61K35/14 , A61K38/00 , A61K38/16 , C12R1/91
摘要： PURPOSE: To obtain the titled factor, by cultivating cells derived from human T lymphocytes in a culture medium containing a specific stimulating agent.
CONSTITUTION: Cells derived from human T lymphocytes, e.g. T lymphocytes derived from human peripheral blood, T lymphomatous cells, T leukemic cells or T cellular hybridized strains, are cultivated in a culture medium containing a polysaccharide, e.g. having (1→3) glucoside bonds in the main chain, or a bacterial cellular component, e.g. a bacterial cell of Streptococcus pyogenes, picibanil or cell wall skeletonic component of a bacterium of the genus Nocardia, having the immunological activating action as a stimulating agent to the aimed more selective colony stimulating factor (CFS) with little contamination by other lymphokines. The resultant CFS is useful as medicines for treating human hypogranulocytosis, etc. The above-mentioned CFS has 15,000W45,000 daltons molecular weight and is inactivated by treatment with trypsin, etc. without inactivation by treatment at 37°C for 2hr with deoxyribonucleases (DNAases) or ribonucleases (RNAases).
COPYRIGHT: (C)1984,JPO&Japio
摘要翻译：目的：通过在含有特定刺激剂的培养基中培养源自人T淋巴细胞的细胞来获得标题因子。构成：源自人T淋巴细胞的细胞，例如在来自人外周血，T淋巴细胞，T白血病细胞或T细胞杂交菌株的T淋巴细胞培养在含有多糖的培养基中，在主链中具有（13）葡糖苷键，或细菌细胞组分，例如，具有作为刺激剂的免疫激活作用的目的多选择性集落刺激因子（CFS），其中很少被其他淋巴因子污染的细菌细菌，化脓性链球菌（Streptococcus pyogenes）的细菌细胞，pic an il或细胞壁骨骼组分。所得CFS可用作治疗人类低粒细胞缺乏症的药物等。上述CFS具有15,000-45,000道尔顿分子量，并且通过用胰蛋白酶等处理而灭活，而在37℃下通过用脱氧核糖核酸酶处理2小时而灭活 DNAase）或核糖核酸酶（RNAase）。

2. 发明专利

JPS59139349A Polypeptide 失效
标题翻译：多肽
公开(公告)号：JPS59139349A
公开(公告)日：1984-08-10
申请号：JP23037282
申请日：1982-12-29
申请人： Ajinomoto Co Inc , Japan Found Cancer
发明人： TANIGUCHI KORETSUGU , SUGANO HARUO , MATSUI YUTAKA , YOSHIMOTO RIYOUTA , HAMURO JIYUNJI
IPC分类号： C12N15/09 , A61K38/00 , A61P37/00 , C07K14/00 , C07K14/52 , C07K14/54 , C07K14/55 , C12P21/00 , C12P21/02
CPC分类号： C07K14/55
摘要： NEW MATERIAL:The polypeptide of formula wherein one or plural amino acids in the amino acid sequence may be deleted from its N-terminal, and having interleukin 2 activity. USE:It has nterleukin 2 activity and is useful as a remedy for immune diseases such as cancer, bacteriosis, viral diseases, immunoinsufficiency, autoimmune diseases, etc. PROCESS:Dulcat 111 cell strain capable of producing interleukin 2 is cultured, and extracted. The 11-12 smRNA fraction containing interleukin 2-mRNA is eluted from RNA obtained by the extraction. cDNA is synthesized from the fraction in vitro to obtain the plasmid vector PBR322 and a recombinant DNA, which is inserted into Escherichia coli X1766. The bacterial strain is cultured to obtain a plasmid DNA fraction, which is digested completely with restriction enzyme PstI to separate the DNA coding the objective peptide.
摘要翻译：新材料：其中氨基酸序列中的一个或多个氨基酸可以从其N末端缺失并具有白细胞介素2活性的多肽。用途：具有白细胞介素2活性，可用作癌症，细菌病，病毒性疾病，免疫缺陷病毒，自身免疫性疾病等免疫疾病的治疗方法。方法：培养能够产生白细胞介素2的Dulcat 111细胞株，提取。从提取得到的RNA中洗脱含有白介素2-mRNA的11-12个smRNA级分。从该级分体外合成cDNA，得到质粒载体PBR322和重组DNA，其插入大肠杆菌X1766中。培养菌株以获得质粒DNA级分，其用限制酶PstI完全消化以分离编码目标肽的DNA。

3. 发明专利

JPS5939832A Monoclonal antibody and preparation and use thereof 失效
标题翻译：单克隆抗体及其制备及其用途
公开(公告)号：JPS5939832A
公开(公告)日：1984-03-05
申请号：JP14975382
申请日：1982-08-28
申请人： Ajinomoto Co Inc
发明人： YOSHIMOTO RIYOUTA , HANZAWA YOSHIAKI , HAMURO JIYUNJI
IPC分类号： C12N15/02 , A61K39/395 , C07K1/22 , C07K14/005 , C07K14/195 , C07K14/52 , C07K14/54 , C07K14/55 , C07K16/00 , C07K16/24 , C07K19/00 , C12P21/08 , G01N33/68
CPC分类号： C07K14/55 , C07K16/246 , G01N33/6869 , Y10S435/948 , Y10S530/864
摘要： PURPOSE: To obtain the titled antibody, by forming a hybridoma between a cell capable of producing an antibody of an animal immunized with a human interleukin and a myelomatous cell, cloning the hybriodoma, and selecting and using the specific clone.
CONSTITUTION: A hybridoma is formed between a cell, capable of producing an antibody, and present in a spleen or cell in a lymphatic node of an animal immunized with a human interleukin 2 (IL2) and a myelomatous cell (a malignant cell from an initial tumor of a marrow), a cultivated and cloned to select clone capable of producing an antibody exhibiting the specificity for the human IL2. The resultant supernatant liquid obtained by cultivating the above-mentioned clone is purified by the purification operation, e.g. salting out or ion exchange chromatography, etc. to recover the aimed monoclonal antibody.
EFFECT: A very small amount of the IL2 can be determined in a high sensitivity by carrying out the radioimmunoassay or enzymic immunoassay with the above- mentioned clone.
COPYRIGHT: (C)1984,JPO&Japio
摘要翻译：目的：通过在能够产生用人白细胞介素免疫的动物的抗体和骨髓细胞的细胞的细胞之间形成杂交瘤，克隆杂交瘤，选择和使用特异性克隆来获得标题抗体。构成：在能够产生抗体的细胞和存在于用人白细胞介素2（IL2）和骨髓细胞免疫的动物的淋巴结中的脾脏或细胞中的细胞之间形成杂交瘤（来自初始培养和克隆以选择能够产生对人IL2具有特异性的抗体的克隆。将上述克隆培养得到的上清液通过纯化操作纯化，盐析或离子交换色谱等，以回收目标单克隆抗体。效果：通过用上述克隆进行放射免疫测定或酶免疫测定，可以高灵敏度地测定非常少量的IL2。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式